A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
Status:
Completed
Trial end date:
2012-04-20
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary
purpose of this study is to determine the safety profile, establish the maximum tolerated
dose, and inform the phase 2 dose of IXAZOMIB administered intravenously in participants with
nonhematologic malignancies.